224 related articles for article (PubMed ID: 37328193)
1.
Chitturi P; Xu S; Ahmed Abdi B; Nguyen J; Carter DE; Sinha S; Arora R; Biernaskie J; Stratton RJ; Leask A
Ann Rheum Dis; 2023 Sep; 82(9):1191-1204. PubMed ID: 37328193
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Regulation of Skin Fibrosis in Systemic Sclerosis by Apelin/APJ Signaling.
Yokoyama Y; Sekiguchi A; Fujiwara C; Uchiyama A; Uehara A; Ogino S; Torii R; Ishikawa O; Motegi SI
Arthritis Rheumatol; 2018 Oct; 70(10):1661-1672. PubMed ID: 29676521
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.
Toyama T; Looney AP; Baker BM; Stawski L; Haines P; Simms R; Szymaniak AD; Varelas X; Trojanowska M
J Invest Dermatol; 2018 Jan; 138(1):78-88. PubMed ID: 28870693
[TBL] [Abstract][Full Text] [Related]
4. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
[TBL] [Abstract][Full Text] [Related]
5. The yes-associated protein-1 (YAP1) inhibitor celastrol suppresses the ability of transforming growth factor β to activate human gingival fibroblasts.
Naik A; Chitturi P; Nguyen J; Leask A
Arch Oral Biol; 2024 Apr; 160():105910. PubMed ID: 38364717
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
[TBL] [Abstract][Full Text] [Related]
7. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
[TBL] [Abstract][Full Text] [Related]
8. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
[TBL] [Abstract][Full Text] [Related]
9. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
[TBL] [Abstract][Full Text] [Related]
10. Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis.
Xie X; Gan H; Tian J; Li F; Chen J; Wang J; Liao J; Li S
Eur J Clin Invest; 2022 Aug; 52(8):e13791. PubMed ID: 35441708
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
Avouac J; Palumbo K; Tomcik M; Zerr P; Dees C; Horn A; Maurer B; Akhmetshina A; Beyer C; Sadowski A; Schneider H; Shiozawa S; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheum; 2012 May; 64(5):1642-52. PubMed ID: 22139817
[TBL] [Abstract][Full Text] [Related]
13. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
14. Impaired Mitochondrial Transcription Factor A Expression Promotes Mitochondrial Damage to Drive Fibroblast Activation and Fibrosis in Systemic Sclerosis.
Zhou X; Trinh-Minh T; Tran-Manh C; Gießl A; Bergmann C; Györfi AH; Schett G; Distler JHW
Arthritis Rheumatol; 2022 May; 74(5):871-881. PubMed ID: 34807516
[TBL] [Abstract][Full Text] [Related]
15. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
[TBL] [Abstract][Full Text] [Related]
17. Antifibrotic effects of crocetin in scleroderma fibroblasts and in bleomycin-induced sclerotic mice.
Song Y; Zhu L; Li M
Clinics (Sao Paulo); 2013 Oct; 68(10):1350-7. PubMed ID: 24212843
[TBL] [Abstract][Full Text] [Related]
18. X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc).
Bergmann C; Hallenberger L; Chenguiti Fakhouri S; Merlevede B; Brandt A; Dees C; Zhu H; Zehender A; Zhou X; Schwab A; Chen CW; Györfi AH; Matei AE; Chakraborty D; Trinh-Minh T; Rauber S; Coras R; Bozec A; Kreuter A; Ziemer M; Schett G; Distler JHW
Ann Rheum Dis; 2021 Aug; 80(8):1048-1056. PubMed ID: 33903093
[TBL] [Abstract][Full Text] [Related]
19. cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis.
Worrell JC; Leslie J; Smith GR; Zaki MYW; Paish HL; Knox A; James ML; Cartwright TN; O'Reilly S; Kania G; Distler O; Distler JHW; Herrick AL; Jeziorska M; Borthwick LA; Fisher AJ; Mann J; Mann DA; Oakley F
Rheumatology (Oxford); 2020 Dec; 59(12):3939-3951. PubMed ID: 32725139
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.
Zhang Y; Dees C; Beyer C; Lin NY; Distler A; Zerr P; Palumbo K; Susok L; Kreuter A; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2015 May; 74(5):936-43. PubMed ID: 24431397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
